Ir al contenido principal Ir al menú de navegación principal Ir al pie de página del sitio

Cannabis medicinal: más allá del mito, solo otra droga (vegetal)

https://doi.org/10.18294/sc.2022.4078

Publicado May 6, 2022 Open Access


Paulo Cáceres Guido Farmacéutico. Especialista en Farmacia Hospitalaria. Responsable, Unidad de Farmacocinética e Investigación en Farmacología Clínica, Área de Farmacia, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Ciudad Autónoma de Buenos Aires, Argentina. image/svg+xml



Vistas de resumen
877
Cargando métricas ...


Palabras claves:

Cannabis sativa, Medicamentos, Política de Salud, Cannabis Medicinal


Resumen


En este editorial, se propone un breve recorrido por algunas distinciones entre drogas y fármacos y definiciones sobre Cannabis sativa y su uso en una nueva industria legal. Por otro lado, se aborda la toxicidad del cannabis medicinal, sus usos sociales, la acción farmacológica, las paradojas legales, y la revolución científica que ha generado el estudio del sistema endocannabinoide y que ha sido de gran relevancia para la fisiología y la farmacología moderna.


Referencias bibliográficas


1. Métodos generales de Farmacognosia [Internet]. 2013 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/4y6js7sd.

2. Wadud A, Prasad PV, Rao MM, Narayana A. Evolution of drug: a historical perspective. Bulletin of the Indian Institute of History of Medicine (Hyderabad). 2007;37(1):69-80.

3. Pain S. A potted history. Nature. 2015;525(7570):S10-S11.

4. Chang C, Bowman JL, Meyerowitz EM. Field guide to plant model systems. Cell. 2016;167(2):325-339.

5. Verpoorte R. Pharmacognosy in the new millennium: leadfinding and biotechnology. Journal of Pharmacy and Pharmacology. 2000;52(3):253-262.

6. Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26(9):2774.

7. Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic use in clinical practice. International Journal of Molecular Sciences. 2022;23(6):3344.

8. Nahar L, Uddin SJ, Alam MA, Sarker SD. Extraction of naturally occurring cannabinoids: an update. Phytochemical Analysis. 2021;32(3):228-241.

9. Donnan J, Shogan O, Bishop L, Swab M, Najafizada M. Characteristics that influence purchase choice for cannabis products: a systematic review. Journal of Cannabis Research. 2022;4(1):9.

10. Zimniewska M. Hemp fibre properties and processing target textile: A review. Materials. 2022;15(5):1901.

11. Odieka AE, Obuzor GU, Oyedeji OO, Gondwe M, Hosu YS, Oyedeji AO. The medicinal natural products of Cannabis sativa Linn.: A review. Molecules. 2022;27(5):1689.

12. Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149.

13. Americaeconomia. Cannabis en América Latina: industria supera los US$ 170 millones en 2021 y prevé explosivo aumento para 2026 [Internet]. 2021 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/ynv6c9jj.

14. Castillo-Carniglia A, Rivera-Aguirre A, Calvo E, Queirolo R, Keyes KM, Cerdá M. Trends in marijuana use in two Latin American countries: an age, period and cohort study. Addiction. 2020;115(11):2089-2097.

15. Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. In: StatPearls. Treasure Island: StatPearls Publishing; 2022.

16. Shanahan M, Cyrenne P. Cannabis policies in Canada: How will we know which is best? International Journal of Drug Policy. 2021;91:102556.

17. Kochen S. Medical cannabis. Salud Colectiva. 2022;18:e3991.

18. Shankar PR. VigiAccess: Promoting public access to VigiBase. Indian J Pharmacol. 2016;48(5):606-607.

19. VigiAccess [Internet]. Uppsala Monitoring Centre, 2022 [citado 20 abr 2022]. Disponible en: http://www.vigiaccess.org/

20. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. New England Journal of Medicine. 2014;370(23):2219-2227.

21. Schep LJ, Slaughter RJ, Glue P, Gee P. The clinical toxicology of cannabis. New Zealand Medical Journal. 2020;133(1523):96-103.

22. Urits I, Charipova K, Gress K, Li N, Berger AA, Cornett EM, et al. Adverse effects of recreational and medical cannabis. Psychopharmacology Bulletin. 2021;51(1):94-109.

23. Blohm E, Sell P, Neavyn M. Cannabinoid toxicity in pediatrics. Current Opinion in Pediatrics. 2019;31(2):256-261.

24. Montoya Z, Conroy M, Vanden Heuvel BD, Pauli CS, Park SH. Cannabis contaminants limit pharmacological use of cannabidiol. Frontiers in Pharmacology. 2020;11:571832.

25. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: A systematic review and meta-analysis [correction in JAMA Network Open. 2020;3(1):e1921065]. JAMA Network Open. 2019;2(11):e1916318.

26. Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes & Control. 2013;24(10):1811-20.

27. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.

28. Winters KC, Lee CY. Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age. Drug Alcohol Depend. 2008;92(1-3):239-247.

29. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nature reviews: Neuroscience. 2016;17(5):293-306.

30. Karila L, Benyamina A. Addictions. Revue des Maladies Respiratoires. 2019;36(2):233-240.

31. Maldonado R, Berrendero F, Ozaita A, Robledo P. Neurochemical basis of cannabis addiction. Neuroscience. 2011;181:1-17.

32. Cook J, Lloyd-Jones DM, Ogden E, Bonomo Y. Medical use of cannabis: an addiction medicine perspective. Internal Medicine Journal. 2015;45(6):677-680.

33. Madruga CS, Miguel AQC, Massaro LTDS, Caetano R, Laranjeira R. Cannabis consumption onset and addiction: Data from the Second Brazilian Drugs and Alcohol Survey (BNADS). Journal of Psychoactive Drugs. 2021:1-9.

34. National Institutes of Health. ¿La marihuana es adictiva?: El Canabis (marihuana) – Reporte de investigación [Internet]. National Institute on Drug Abuse; 2020 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/32w8awck.

35. O’Grady C. Cannabis research data reveals a focus on harms of the drug. Science. 2020;369(6508):1155.

36. Kasuda S, Kondo T, Terazawa I, Morimoto M, Yuui K, Kudo R. Cardiac sudden death in a young cannabis user. Legal Medicine (Tokyo). 2021;53:101955.

37. Delteil C, Sastre C, Piercecchi MD, Faget-Agius C, Deveaux M, Kintz P, et al. Death by self-mutilation after oral cannabis consumption. Legal Medicine (Tokyo). 2018;30:5-9.

38. Nappe TM, Hoyte CO. Pediatric death due to myocarditis after exposure to cannabis. Clinical Practice and Cases in Emergency Medicine. 2017;1(3):166-170.

39. von Both I, Santos B. Death of a young woman with cyclic vomiting: a case report. Forensic Science, Medicine, and Pathology. 2021;17(4):715-722.

40. Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T. Sudden unexpected death under acute influence of cannabis. Forensic Science International. 2014;237:e11-13.

41. Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid Hyperemesis Syndrome: Reports of fatal cases. Journal of Forensic Sciences. 2019;64(1):270-274.

42. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research. 2017;2(1):139-154.

43. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756-1764.

44. Cuando fumar era “beneficioso” para la salud. El País [Internet]. 2008 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/j46zt9me.

45. Tabaco [Internet]. WHO; 2022 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/msasmb64.

46. Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. CMAJ. 2020;192(9):e206.

47. Lopera V, Rodríguez A, Amariles P. Clinical relevance of drug interactions with cannabis: A systematic review. Journal of Clinical Medicine. 2022;11(5):1154.

48. Cáceres Guido P, Riva N, Caraballo R, Reyes G, Huaman M, Gutierrez R, et al. Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy. Epilepsia. 2021;62(1):e7-e12.

49. Schaiquevich P, Riva N, Maldonado C, Vázquez M, Cáceres-Guido P. Clinical pharmacology of cannabidiol in refractory epilepsy. Farmacia Hospitalaria. 2020;44(5):222-229.

50. Ministerio de Salud. Cannabidiol en epilepsia resistente a fármacos [Internet]. 2022 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/mt4azda6.

51. Ministerio de Salud. El Ministerio de Salud creó la categoría de Productos vegetales a base de cannabis para el uso y aplicación en medicina humana [Internet]. 2022 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/2p8p8f3x.

52. Cáceres Guido P, Riva N, Calle G, Dell’Orso M, Gatto M, Sberna N, et al. Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil. Journal of the American Pharmacists Association. 2020;60(1):212-215.

53. Hicks A. Prestigious Harvey Prize, a predictor of the Nobel, goes to Raphael Mechoulam [Internet]. Ministerio de Salud; 2020 [citado 20 abr 2022]. Disponible en: https://tinyurl.com/2p9ceu3s.